MTOR and interstitial lung disease: Five patients discontinued mTOR inhibitors within the first 2 years of study period because of various side effects, 1 due to severe aphthous and colonic ulcers, 1 due to hemolytic uremic syndrome, 1 due to severe gastrointestinal upset, 1 due to interstitial lung disease and `1 due to increasing proteinuria.